DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 203585/S-005

SUPPLEMENT APPROVAL

Teva Pharmaceuticals International GmbH
c/o Teva Branded Pharmaceuticals Products R&D, Inc.
Attention: Donald F. Hora, Jr.
Senior Manager, Global Labeling and Brands Management
41 Moores Road
P.O. Box 4011
Frazer, PA 19355

Dear Mr. Hora:

Please refer to your Supplemental New Drug Application (sNDA) dated December 21, 2016, received December 21, 2016, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Synribo® (omacetaxine mepesuccinate) for injection, 3.5 mg/vial.

This Prior Approval supplemental new drug application provides for updates to the US Prescribing Information subsection 12.3 Pharmacokinetics – Elimination based on results from the Study C41443/1103 entitled, "*An open-label study to investigate the Pharmacokinetics (Absorption, Distribution, Metabolism, and Excretion) of Omacetaxine Mepesuccinate following subcutaneous administration of [^{14}C] Omacetaxine Mepesuccinate in patients with relapsed and/or refractory hematologic malignancies or advanced solid tumors*" to fulfill PMR 1930-3.

In addition, other revisions to the labeling included the following: the change in Teva's contact information to report suspected adverse reactions; the deletion of sections 7 Drug Interactions, 8.6 Renal Impairment, and 8.7 Hepatic Impairment; the relocation of QT prolongation risk assessment to subsection 12.2 Pharmacodynamics resulting in the deletion of subsection 12.6 Assessment for Risk of QT Prolongation; and other minor changes.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "*SPL Standard for Content of Labeling Technical Qs and As*" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Thomas Iype, PharmD, Regulatory Project Manager, at (240) 402-6861.

Sincerely,

{See appended electronic signature page}

Albert Deisseroth, MD, PhD
Supervisory Associate Division Director
Division of Hematology Products
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ALBERT B DEISSEROTH
06/21/2017